Interim safety and efficacy data to be reported in Q1VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa ...
Processa Pharmaceuticals (PCSA) reported that it completed the enrollment and dosing of the 20 patients required for the planned formal interim ...
ORLANDO, FL / ACCESS Newswire / December 26, 2025 / RedChip Companies will air interviews with Processa Pharmaceuticals, Inc.
VERO BEACH, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today ...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after ...
Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine Company on track to conduct forma ...
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) stock is skyrocketing on Wednesday, with a session volume of 2.73 million compared to the average volume of 389.09 thousand, as per data from Benzinga Pro ...
Investing.com -- Processa Pharmaceuticals Inc (NASDAQ:PCSA) stock surged 23.8% Wednesday after the company released preliminary Phase 2 data showing its Next Generation Cancer therapy demonstrated ...
Processa Pharmaceuticals ( (PCSA)) just unveiled an announcement. On December 12, 2025, Processa Pharmaceuticals announced a 1-for-25 reverse stock split of its common stock, effective December 16, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback